Impax Laboratories, Inc.
NASDAQTotal Valuation
Impax Laboratories, Inc. carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 1.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | - - |
| Enterprise Value | 1.80B |
Share Statistics
Impax Laboratories, Inc. currently has 73.99M shares outstanding.
| Shares Outstanding | 73.99M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.54, and the price-to-book ratio stands at -3.22.
| PE Ratio | N/A |
| PS Ratio | 1.54 |
| PB Ratio | -3.22 |
| P/TBV Ratio | -4.23 |
| P/FCF Ratio | 10.78 |
| P/OCF Ratio | 14.21 |
Enterprise Valuation
| EV / Sales | 2.32 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 11.77 |
Financial Position
Impax Laboratories, Inc. maintains a current ratio of 1.96, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 420.60, indicating elevated leverage, while an interest coverage ratio of -5.86 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.96 |
| Quick Ratio | 1.37 |
| Debt / Equity | 420.60 |
| Debt / EBITDA | -3.33 |
| Interest Coverage | -5.86 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -29.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.79 |
Taxes
| Income Tax | 18.33M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Impax Laboratories, Inc.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 19.60, while the 200-day moving average is 19.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 19.60 |
| 200-Day Moving Average | 19.16 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Impax Laboratories, Inc. generated 775.79M in revenue and converted that into -469.29M in net income, yielding earnings per share of -6.53. EBITDA reached -236.68M, while operating income came in at -346.13M.
| Revenue | 775.79M |
| Gross Profit | 143.80M |
| Operating Income | -346.13M |
| Pretax Income | -450.96M |
| Net Income | -469.29M |
| EBITDA | -236.68M |
| EBIT | -346.13M |
| Earnings Per Share (EPS) | -6.53 |
Balance Sheet
Impax Laboratories, Inc. holds 181.78M in cash and equivalents against 787.37M in total debt, resulting in a net debt position of 605.59M. Total book value stands at -371.70M, with working capital of 341.32M providing operational flexibility.
| Cash & Cash Equivalents | 181.78M |
| Total Debt | 787.37M |
| Net Debt | 605.59M |
| Equity (Book Value) | -371.70M |
| Book Value Per Share | -5.17 |
| Working Capital | 341.32M |
Cash Flow
Impax Laboratories, Inc. produced 84.22M in operating cash flow over the past twelve months. After subtracting -26.80M in capital expenditures, free cash flow totaled 57.42M - equivalent to 0.80 per share.
| Operating Cash Flow | 84.22M |
| Capital Expenditures | -26.80M |
| Free Cash Flow | 57.42M |
| FCF Per Share | 0.80 |
Margins
Impax Laboratories, Inc. operates with a gross margin of 18.54, reflecting its pricing power and cost economics. The operating margin of -44.62 and net profit margin of -60.49 provide insight into operational efficiency.
| Gross Margin | 18.54 |
| Operating Margin | -44.62 |
| Pretax Margin | -58.13 |
| Profit Margin | -60.49 |
| EBITDA Margin | -30.51 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 6.16 |
| FCF Yield | 9.28 |
Scores
Impax Laboratories, Inc. posts an Altman Z-Score of 0.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.07 |